Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
AssigneeBoard of Regents, The University of Texas System
InventorsBarrett R. Harvey, Kenneth L. Pinkston, Ali Azhdarina, Eva M. Sevick-Muraca
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.
Claims14
An isolated monoclonal antibody, wherein the antibody specifically binds to a EpCAM polypeptide and comprises:
- (a) a first VH CDR of the 7 monoclonal antibody (SEQ ID NO:
- 9);
- (b) a second VH CDR of the 7 monoclonal antibody (SEQ ID NO:
- 10);
- (c) a third VH CDR of the 7 monoclonal antibody (SEQ ID NO:
- 11);
- (d) a first VL CDR of the 7 monoclonal antibody (SEQ ID NO:
- 12);
- (e) a second VL CDR of the 7 monoclonal antibody (SEQ ID NO:
- 13);
- and
- (f) a third VL CDR of the 7 monoclonal antibody (SEQ ID NO:
- 14).
Dependencies are inferred from the claim text.